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ABSTRACT The nicotinic cholinergic system exerts potent modulatory effects on
glutamatergic neurotransmission, an effect mediated in part by increased glutamate
release following activation of presynaptic nicotinic cholinergic receptors. Ionotropic
glutamate receptor agonists also stimulate release of acetylcholine, suggesting that
these neurotransmitter systems reciprocally regulate one another. We investigated an
interface between the nicotinic cholinergic and glutamatergic systems by measuring
nicotinic receptor subunit transcript expression following administration of 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX), an antagonist of the AMPA and kainate subtypes of
glutamate receptors. Using [35S] in situ hybridization, we measured expression of 2, 3,
4, 5, 7, 2, 3, and 4 nicotinic receptor subunit transcripts in the rat forebrain.
Following 7 days of treatment with vehicle or CNQX (1 mg/kg/day or 10 mg/kg/day),
changes in nicotinic receptor subunit transcript expression were restricted to subunits
that form heteromeric receptors. We found increased levels of transcripts for 2 and 2
nicotinic receptor subunits in the hippocampus, decreased 4 subunit transcripts in the
medial habenula and amygdala, and increased 2 subunit transcripts in the septum and
piriform cortex. We did not detect changes in expression of transcripts for the 7
subunit, which forms homomeric nicotinic receptors. Our findings indicate that expres-
sion of nicotinic cholinergic receptor subunit transcripts are regulated in a subunit- and
region-specific fashion by CNQX, an antagonist of non-NMDA ionotropic glutamate
receptors. Synapse 52:62–72, 2004. © 2004 Wiley-Liss, Inc.
INTRODUCTION
Multiple studies have shown increased release of
glutamate, GABA, and other neurotransmitters follow-
ing presynaptic activation of nicotinic cholinergic re-
ceptors, contributing to a growing literature detailing
the potent modulatory effects of the nicotinic cholin-
ergic system (NCS) in the brain (McGehee et al., 1995;
Lendvai et al., 1996; Alkondon et al., 1997; Aramakis
and Metherate, 1998; Gioanni et al., 1999; Grillner and
Svensson, 2000; Reuben et al., 2000; Alkondon and
Albuquerque, 2001). The neuronal nicotinic cholinergic
receptor (nAChR) is a ligand-gated ion channel abun-
dantly expressed in cortical and subcortical structures
(Itier and Bertrand, 2001). The native ligand for
nAChRs, acetylcholine (ACh), is released from a rela-
tively small number of cholinergic neurons that
broadly innervate most areas of the brain (McGehee
and Role, 1995; Dani, 2001). Nicotinic receptors are
comprised of assemblies of subunits encoded by specific
genes, 2–10, and 2–4 (Itier and Bertrand, 2001).
These subunits can form either heteromeric (2–6,
2–4) or homomeric (7–10) receptors (Picciotto et
al., 2001). Several nicotinic receptors with specific com-
binations of subunits have been identified and charac-
terized. The high-affinity [3H]-nicotine binding site
that accounts for 90% of the nicotinic sites in the brain
is a pentamer comprised of obligate 2 and 4 subunits
in combination with 5, 6, 3, and/or 4 (Gotti et al.,
1997; Court et al., 2000; Picciotto et al., 2001). Nicotinic
receptors containing an 3 subunit are associated with
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binding to neuronal bungarotoxin. The 7, 8, and 9
subunits form pentameric homomers that bind -bun-
garotoxin. Neuronal nicotinic receptors permit calcium
entry into the cell following binding by two ACh mole-
cules to a site associated with the  subunits. Nicotinic
receptors desensitize following exposure to agonist, an
effect whose duration depends on receptor subunit
composition (Itier and Bertrand, 2001; Picciotto et al.,
2001). The high-affinity [3H]-nicotine binding sites are
highly expressed in the striatum and substantia nigra,
with lower levels of expression in the neocortex and
hippocampus (Court et al., 2000). Neuronal bungaro-
toxin sites are highly expressed in the hippocampus
and neocortex, while -bungarotoxin sites are ex-
pressed in the hippocampus, midbrain, neocortex, and
striatum (Court et al., 2000).
A number of studies have examined interactions be-
tween the nicotinic and glutamatergic neurotransmit-
ter systems (Ramoa et al., 1990; Rasmusson et al.,
1996; Shoaib et al., 1997). Administration of nicotine to
slices of rat auditory cortex enhanced NMDA-receptor
mediated excitatory postsynaptic potentials, while in-
tracerebral microdialysis experiments demonstrated
increased synaptic glutamate levels following applica-
tion of nicotine (Aramakis and Metherate, 1998; Gio-
anni et al., 1999). Other work has demonstrated in-
creased hippocampal ACh release following application
of glutamate receptor agonists by retrograde microdi-
alysis into the medial septum or the hippocampus
(Moor et al., 1996). Similar effects on ACh release were
reported in the striatum, suggesting that glutamate
receptors can modulate activation of the NCS (Ikarashi
et al., 1998; Knauber et al., 1999). These data suggest
that the nicotinic cholinergic and glutamatergic neuro-
transmitter systems are integrated and reciprocally
regulate one another.
Glutamatergic neurotransmission involves presyn-
aptic release of glutamate, activation of pre- and
postsynaptic glutamate receptors, and tightly regu-
lated reuptake of glutamate from the synaptic cleft
(Danbolt, 2001). Glutamate receptor subtypes include
three families of pharmacologically distinct ligand-
gated ion channels (N-methyl-D-aspartate (NMDA),
-amino-3-hydroxy-5-methylisoxazole-4-propionic acid
(AMPA), and kainate (KA) receptors) as well as the
G-protein-coupled metabotropic receptors (mGluR1–
mGluR8) (Nakanishi, 1992; Hollmann and Heine-
mann, 1994; Bleakman and Lodge, 1998). NMDA re-
ceptor-mediated depolarization of the postsynaptic
neuron is preceded by localized depolarization via ac-
tivation of AMPA receptors. This localized depolariza-
tion permits removal of Mg2-mediated open channel
blockade of NMDA receptors. The presynaptically lo-
calized KA receptors contribute to regulation of synap-
tic function by modulating neuronal glutamate release
and astrocytic glutamate reuptake (Claudio et al.,
2000; Delaney and Jahr, 2002).
The glutamate neurotransmitter system interacts
with other neurotransmitters throughout the brain.
Many of these interactions are mediated by the activ-
ities of AMPA and KA receptors. For example, AMPA
receptor antagonists mediate region- and circuit-spe-
cific release of ACh, dopamine, and serotonin, while
activation of serotonin or dopamine receptor subtypes
modulate AMPA receptor subunit expression (Naudon
et al., 1992; Meador-Woodruff et al., 1996; Moor et al.,
1996; Martin-Ruiz et al., 2001; Cai et al., 2002; Chao et
al., 2002; Wu et al., 2002; Ghersi et al., 2003). The
effects of AMPA and KA receptor modulation on ex-
pression of nicotinic receptor expression have not pre-
viously been reported. The purpose of this study was to
investigate the modulatory effects of AMPA and KA
receptors on the nicotinic cholinergic system. We uti-
lized CNQX, an AMPA and KA receptor antagonist, to
investigate the regulation of brain nicotinic receptor
subunit transcript expression by the AMPA and KA
receptors.
MATERIALS AND METHODS
Animals and tissue preparation
Three groups of 10 adult, male Sprague-Dawley rats
(250 g) were treated with daily subcutaneous injections
of CNQX (1 or 10 mg/kg) or vehicle (DMSO) for 7 days.
These doses were selected based on previous studies
that have demonstrated biochemical or behavioral
changes following subchronic CNQX treatment (Healy
and Meador-Woodruff, 1999; Mead and Stephens,
1999). Twenty-four hours after the last injection,
brains from sacrificed animals were removed, rapidly
frozen in isopentane (–30°C), and stored at –80°C until
sectioned. Each brain was thawed for 30 min to a
temperature of –20°C and mounted for cryostat sec-
tioning. Ten-m sections were mounted on polylysine-
subbed microscope slides, desiccated overnight at 4°C,
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In situ hybridization
Primers for polymerase chain reaction (PCR) ampli-
fication were designed for each cholinergic receptor
subunit of interest using Primer3 (http://waldo.wi.mit.
edu/c/s.dll/primer/primer3) and AMPLIFY (http://
www.wisc.edu/genetics/CATG/amplify/index.html; Bill
Engels, Madison, WI). Unique areas of the rat 2 (Gen-
Bank accession #L10077, coding region 1321–1718), 3
(X03440, 1223–1742), 4 (L31620, 1114–1642), 5
(NM_017978, 447–906), 7 (NM_012832, 125–624), 2
(U42976, 147–562), 3 (J04636, 1153–1632), and 4
(L31622, 1251–1747) subunits were targeted for ampli-
fication from full-length rat clones of each subunit (gen-
erously provided by Dr. Daniel Goldman, University of
Michigan, Ann Arbor, MI). Due to the occurrence of
significant regions of homology between sequences for
the 2, 4, and 2 subunits, we performed two-way
BLAST analysis of the full-length cDNAs to confirm
that our probes were designed to specifically recognize
their intended targets. Following amplification, DNA
was extracted and purified with the QIAquick Gel Ex-
traction Kit (Qiagen, Valencia, CA), subcloned using
the Zero Blunt TOPO PCR Cloning Kit (Invitrogen,
Carlsbad, CA), and sequenced (Thermo Sequenase Ra-
diolabeled Termination Cycle Sequencing Kit, USB,
Cleveland, OH). For riboprobe synthesis, 10 l of [35S]-
UTP was dried and 2.0 l 5 transcription buffer, 1.0
l 0.1M DTT, 1.0 l each of 10 mM ATP, CTP, and
GTP, 2.0 l linearized plasmid DNA, 0.5 l RNase
inhibitor, and 1.5 l T3 or T7 RNA polymerase were
combined and incubated for 2 h at 37°C. Then 1.0 l
DNase (RNase-free) was added and the mixture was
incubated for 15 min at room temperature (RT). Radio-
labeled probe was purified with microspin chromatog-
raphy columns (Bio-Rad, Hercules, CA). Two slides per
level for each probe were removed from 80°C and
placed in 4% (weight:vol) formaldehyde at RT for 1 h.
The slides were then washed in 2 SSC (300 mM
NaCl / 30 mM sodium citrate, pH 7.2) three times for 5
min each. Slides were washed in deionized water for 1
min and placed in 0.1M triethanolamine, pH 8.0 / acetic
anhydride, 400:1 (vol:vol) on a stir plate for 10 min. A
final wash was in 2 SSC for 5 min, followed by dehy-
dration through graded alcohols and air-drying for 30
min. A coverslip with 30 l of riboprobe (1 million cpm,
75% formamide buffer (75% formamide, 10% dextran
sulfate, 3 SSC, 50 mM Na2HPO4 (pH 7.4), 10 mM
dithiothreitol, 1 Denhardt’s solution, 100 g/ml yeast
tRNA), 0.01M DTT) was placed on each slide. Slides
were placed in a covered tray with a filter paper liner
saturated with 75% formamide. After overnight incu-
bation at 55°C, coverslips were removed and the slides
were placed in 2 SSC for 5 min, followed by RNase
(200 g/ml in 10 mM Tris-HCl, pH 8.0 / 0.5 M NaCl) at
37°C for 30 min and then washed as follows: 2 SSC
for 10 min at RT; 1 SSC for 10 min at RT; 0.5 SSC
for 60 min at 55°C; and 0.5 SSC for 10 min at RT. The
slides were dehydrated in graded ethanol solutions,
air-dried, placed in X-ray cassettes, and apposed to
Kodak XAR-5 film for 1–42 days, depending on the
probe.
Image and data analyses
Film was developed and used for quantitative com-
puter image analysis (NIH Image 1.61) as previously
described (Meador-Woodruff et al., 1997). Tissue back-
ground readings were subtracted from duplicate left-
and right-side gray scale values from specific regions of
interest. Background-adjusted gray scale values were
converted into optical density and subsequently aver-
aged, providing one mean value per region per animal
for each probe. Optical density values were converted
to units of bound radiation from a standard curve gen-
erated from a [14C] microscale standard (Amersham
Life Sciences, Buckinghamshire, UK) placed on each
film (Williams, 1982; Downs and Williams, 1984). All
data are expressed as nanocuries per gram of tissue
(nCi/g). Statistical analyses were performed using
analysis of variance and, when appropriate, post-hoc
analyses were by Tukey’s HSD; for all tests,   0.05.
RESULTS
2 Subunit expression and regulation
2 subunit transcripts were expressed in the dentate
gyrus (DG) and throughout the hippocampal subfields
(Fig. 1). In the HPC, we found a main effect for treat-
ment (F(2,105)  74.9, P  0.0001) and region
(F(4,105)  6.23, P  0.0001), but we did not find a
treatment by region interaction (Fig. 2). Post-hoc anal-
ysis revealed increased 2 subunit transcript expres-
sion in the higher-dose CNQX treatment group vs. the
lower-dose CNQX (P  0.0001) and vehicle-treated
groups (P  0.0001) (Fig. 2). The lower dose CNQX-
treated group was not significantly different from the
vehicle-treated group. Significantly higher levels of 2
subunit transcripts were detected in the DG compared
to the four hippocampal subfields (Fig. 2).
4 Subunit
4 subunit transcripts were differentially expressed
in several areas of the rat brain, including the medial
habenula and the amygdala (Fig. 3). In the HPC, we
detected a main effect for region (F(4,95)  13.2, P 
0.0001), but not treatment or treatment by region in-
teraction (Fig. 2). Significantly higher levels of 4 sub-
unit transcripts were detected in the CA1 subfield vs.
the other hippocampal subfields and DG (Fig. 2). We
found a main effect for treatment in the medial habe-
nula (MHN) (F(2,15)  8.56, P  0.003) and in the
amygdala (AMY) (F(2,15)  7.32, P  0.006) (Fig. 4).
Post-hoc analysis revealed significantly lower levels of
4 subunit transcripts in the MHN and AMY for both
the higher (P  0.019, P  0.009, respectively) and
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lower (P  0.002, P  0.005) dose CNQX treatment
groups vs. the control group (Fig. 4). We did not detect
changes in 4 subunit transcript expression in the
cingulate cortex (Cg), parietal cortex (Par), thalamus
(THA), hypothalamus (HT), frontal cortex (Fr), septum
(SEP), HPC, or piriform cortex (Pir) (Fig. 4).
5 Subunit
No treatment effects on 5 subunit mRNA expres-
sion were detected in the Fr, SEP, Cg, MHN, or tem-
poral cortex (Te) (Fig. 5).
7 Subunit
In the HPC, there was a main effect for region (F 
102.8, df 4, 105, P  0.0001), but not treatment, nor
was there a treatment by region interaction (Fig. 2).
Post-hoc analysis revealed significantly lower levels of
mRNA expression in CA1 vs. the other CA subfields
and the DG, as well as lower levels of expression in CA2
vs. CA3 and CA4, lower levels in CA3 vs. CA4, and
higher levels in CA3 and CA4 vs. DG (Fig. 2). There
were no treatment effects on 7 subunit mRNA expres-
sion in the THA, HT, AMY, Par, Cg, Pir, Fr, or SEP
(Fig. 6).
2 Subunit
The 2 subunit mRNA was expressed in multiple
regions of the rat brain, including the septum and
piriform cortex (Fig. 7). In the HPC, we detected a main
effect for CNQX treatment (F  20.3, df 2, 105, P 
0.0001) and region (F  22.8, df 4, 105, P  0.0001), but
no treatment by region interaction (Figs. 1, 2). Post-hoc
analysis revealed significantly higher levels of mRNA
expression in both the higher-dose (P  0.0003) and
lower-dose CNQX treatment groups (P  0.0001) vs.
the control group, and higher levels of mRNA expres-
sion in the higher-dose vs. lower-dose CNQX treatment
group (P  0.014). Post-hoc analysis for region revealed
significantly lower levels of mRNA expression in CA1
vs. the other hippocampal subfields, lower levels of
expression in DG vs. CA2, CA3, and CA4, and higher
levels in CA3 vs. CA4 (Fig. 2). We also found a main
effect for treatment in the SEP (F  3.63, df 2, 20, P 
0.045) and Pir (F  10.8, df 2, 20, P  0.001) (Fig. 8).
Post-hoc analysis revealed higher levels of 2 subunit
expression in the SEP (P  0.035) for the higher-dose
CNQX treatment group vs. the vehicle-treated group.
Post-hoc analysis also revealed higher levels of expres-
sion in the Pir for the higher-dose CNQX treatment
Fig. 1. In situ hybridization using [35S]-labeled antisense probes for the 2 and 2 nicotinic receptor
subunits in the dentate gyrus (DG) and hippocampal subfields CA1, CA2, CA3, and CA4 of rats treated
for 1 week with vehicle or 10 mg/kg/day CNQX. Sections probed for 2 and 2 were exposed to film for
42 and 9 days, respectively.
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group vs. both the vehicle (P  0.001) and lower-dose
CNQX treatment groups (P  0.013). We did not detect
a treatment effect in the Fr, olfactory tubercle (OT),
MHN, Cg, Par, THA, HT, or AMY (Fig. 8).
3, 3, and 4 Subunits
3, 3, and 4 subunit transcripts were restricted to
the MHN. We did not detect an alteration in any of
these subunit transcripts following CNQX treatment
(Fig. 9).
DISCUSSION
In the present study we detected differential regulation
of nicotinic cholinergic receptor subunit transcripts fol-
lowing treatment with the AMPA and the kainate recep-
tor antagonist CNQX (Table I). We found elevated levels
of 2 subunit transcripts in the HPC, SEP, and Pir,
decreased levels of 4 subunit transcripts in the AMY
and MHN, and increased levels of 2 subunit mRNA in
the HPC (Table I). Our findings suggest that gene expres-
sion of nAChR subunits can be regulated by non-NMDA
ionotropic glutamate receptors in a subunit- and region-
specific fashion. These changes in nAChR subunit expres-
sion likely reflect alterations of subunit stoichiometry of
the nAChRs. Since the nAChRs have distinct functional
characteristics based on their subunit composition, alter-
ations in subunit expression affect nAChR activity in the
synapse.
Fig. 2. 2, 4, 7, and 2 nicotinic receptor subunit transcript expression in the dentate gyrus (DG)
and hippocampal subfields following 7 days of CNQX treatment. Expression of 2 (10 mg/kg/day) and 2
(1 mg/kg/day and 10 mg/kg/day) transcripts in rats treated with CNQX was significantly elevated
compared to the vehicle group. There were 10 rats in each treatment group. *P  0.05.
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Numerous studies have demonstrated enhanced re-
lease of glutamate following activation of presynaptic
nAChRs, a process likely mediated by direct calcium
influx or localized depolarization and activation of volt-
age-dependent channels (McGehee et al., 1995; Ara-
makis and Metherate, 1998; Gioanni et al., 1999).
nAChR-mediated calcium influx activates protein ki-
nases and phosphatases, modifying synaptic functions
such as neurotransmitter release (McGehee et al.,
1995; Drew and Werling, 2001). Interestingly, our data
suggest that the interface of the NCS and glutamater-
gic neurotransmission is not limited to nAChR-medi-
ated neurotransmitter release. We found alterations in
2, 4, and 2 nAChR subunit transcript expression
following treatment with CNQX, suggesting that
AMPA and KA receptor activity may directly partici-
pate in the modulation of nAChR function by regulat-
ing the expression of nAChR subunit genes.
There are several mechanisms that could account for
glutamatergic regulation of nAChR expression. Ex-
pression of axon-terminal nAChRs acting as autorecep-
tors could be affected by antagonism of somatoden-
dritic AMPA receptors coexpressed on cholinergic
neurons (Kumamoto and Murata, 1995; Dani, 2001).
Alternatively, expression of subunits that comprise
postsynaptic high affinity (fast) nAChRs may be al-
tered secondary to diminished synaptic ACh levels,
since AMPA-mediated hippocampal ACh release can be
blocked by CNQX treatment (Moor et al., 1996). Other
possible mechanisms include an indirect CNQX-medi-
ated decrease in glutamatergic tone in neuronal cir-
cuits that include cells expressing nAChRs. This is
supported by reports that ACh becomes the primary
excitatory neurotransmitter in the absence of gluta-
mate excitation in primary hypothalamic neuronal cul-
tures (Belousov et al., 2001, 2002). Interestingly, we
detected increased expression of the obligate 2 sub-
unit transcripts in the HPC, SEP, and Pir, a finding
consistent with past observations of augmented nico-
tinic cholinergic function following attenuation of glu-
tamatergic activity by CNQX (Belousov et al., 2001,
2002).
Following treatment with CNQX, we detected in-
creased levels of 2 transcripts in the HPC, increased
2 transcripts in the HPC, SEP, and Pir, and decreased
4 transcripts in the MHN and AMY. In contrast, we
did not detect changes in 7 mRNA expression in the
HPC, AMY, Pir, or SEP with CNQX treatment. The 7
nicotinic subunit exclusively participates in the forma-
tion of a homomeric receptor, while 2, 4, 2, and
Fig. 3. In situ hybridization using [35S]-labeled antisense probes for the 4 nicotinic receptor subunit
in the medial habenula (MHN) and amygdala (AMY) of rats treated for 1 week with vehicle or 10
mg/kg/day CNQX. Sections probed for 4 were exposed to film for 6 days.
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other subunits contribute to the formation of hetero-
meric nicotinic receptor subtypes (Itier and Bertrand,
2001; Picciotto et al., 2001). Thus, our findings suggest
that inhibition of KA and/or AMPA receptors only af-
fects expression of a subset of pharmacologically dis-
tinct nAChRs. Several studies have demonstrated elec-
trophysiological differences between heteromeric
(42) and homomeric (7) nAChRs in the rat hip-
pocampus. 7 selective ligands had no effect on excita-
tory postsynaptic current (EPSC), while 32-specific
compounds, or low concentrations of nicotine itself,
modulate EPSCs in hippocampal slices, suggesting a
non-7 mechanism (Alkondon and Albuquerque, 2002).
In a related study, mediation of inhibition of CA1 py-
ramidal neurons was three times stronger by 42 vs.
7 receptors. (Alkondon and Albuquerque, 2001). Dif-
ferences between heteromeric and homomeric nAChRs
are not limited to the HPC. The 42 antagonist dihy-
dro--erythrodine (DHE) attenuated the excitatory
effects of nicotine on dopaminergic neurons in the ven-
tral tegmental area, while the 7 antagonist methylly-
caconitine (MLA) did not (Grillner and Svensson,
2000).
The differences in neurophysiological function be-
tween heteromeric and homomeric nAChRs may un-
derlie discrete behavioral tasks. For example, Levin et
al. (2002) evaluated the effects on specific memory
tasks of antagonism of 42 vs. 7 containing nAChRs
in the rat. Reference memory was impaired following
administration of the 7 antagonist MLA by cannula in
the HPC, but not the 42 antagonist DHE (Felix and
Levin, 1997; Levin et al., 2002). In contrast, working
memory was impaired following administration of ei-
ther MLA or DHE, suggesting that some cognitive
functions involve differential activation of nAChR sub-
types. The discrete functional roles of the 7 and 42
nAChRs in the HPC are consistent with our findings of
differential nAChR transcript expression following
CNQX treatment, and support our hypothesis that ex-
pression of phenotypically distinct nicotinic receptor
subtypes is differentially regulated by CNQX, a modu-
lator of non-NMDA ionotropic glutamate receptors.
We detected increased 2 and 2 subunit transcript
expression in the HPC following treatment with
CNQX, suggesting either an increase in nicotinic recep-
tors containing these subunits or an alteration in re-
ceptor stoichiometry. In addition, we did not detect
Fig. 4. 4 nicotinic receptor subunit transcript expression in the
frontal cortex (Fr), septum (SEP), piriform cortex (Pir), cingulate
cortex (Cg), parietal cortex (Par), thalamus (THA), medial habenula
(MHN), hypothalamus (HT), and amygdala (AMY) following 7 days of
CNQX treatment. Expression of 4 transcripts in rats treated with 1
mg/kg/day and 10 mg/kg/day CNQX was significantly decreased in the
MHN and in the AMY compared to the vehicle group. There were 10
rats in each treatment group. *P  0.05.
Fig. 5. 5 nicotinic receptor subunit transcript expression in the
frontal cortex (Fr), septum (SEP), cingulate cortex (Cg), temporal
cortex (Te), and medial habenula (MHN) following 7 days of CNQX
treatment. Expression of 5 transcripts did not differ between CNQX-
and vehicle-treated groups. There were 10 rats in each treatment
group.
Fig. 6. 7 nicotinic receptor subunit transcript expression in the
frontal cortex (Fr), septum (SEP), piriform cortex (Pir), cingulate
cortex (Cg), parietal cortex (Par), thalamus (THA), hypothalamus
(HT), and amygdala (AMY) following 7 days of CNQX treatment.
Expression of 7 transcripts did not differ between CNQX- and vehi-
cle-treated groups. There were 10 rats in each treatment group.
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changes in 4 subunit mRNA levels, suggesting that
alterations in nAChR expression following CNQX
treatment are limited to a subset of heteromeric recep-
tor subunits. In the HPC, expression of 2, 3, and 4
subunits has been correlated with medium, fast, and
slow peak rise times, respectively, measured by whole
cell recordings of interneurons in the stratum oriens
and stratum radiatum of the HPC (Sudweeks and
Yakel, 2000). The authors of that study suggested that
2-containing receptors were both a major component
of the total nAChR population in the stratum oriens
and functionally distinct from 3- or 4-containing re-
ceptors (Sudweeks and Yakel, 2000). Thus, an increase
in hippocampal 2 subunit expression, regulated indi-
rectly by CNQX via modulation of AMPA and KA re-
ceptor activity, may lead to a change in nAChR-medi-
ated currents.
We detected decreased 4 subunit transcript expres-
sion in the AMY following treatment with CNQX, sug-
gesting an interaction with the glutamatergic system
in this region. 4 knockout mice have been used to
investigate the contributions of the 4 subunit to nic-
otinic receptor function (Marubio and Changeux,
2000). High-affinity nicotine binding was significantly
attenuated in 4 knockout mice, confirming that this
Fig. 7. In situ hybridization using [35S]-labeled antisense probes for the 2 nicotinic receptor subunit
in the septum (SEP) and piriform cortex (Pir) of rats treated for 1 week with vehicle or 10 mg/kg/day
CNQX. Sections probed for 2 were exposed to film for 9 days.
Fig. 8. 2 nicotinic receptor subunit transcript expression in the
frontal cortex (Fr), septum (SEP), olfactory tubercle (OT), piriform
cortex (Pir), cingulate cortex (Cg), parietal cortex (Par), thalamus
(THA), medial habenula (MHN), hypothalamus (HT), and amygdala
(AMY) following 7 days of CNQX treatment. Expression of 2 tran-
scripts in rats treated with 10 mg/kg/day CNQX was significantly
increased in the SEP and in the Pir compared to the vehicle group.
There were 10 rats in each treatment group. *P  0.05.
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subunit is central for generation of type 2 (42) nico-
tinic currents in many brain areas. 4 knockouts also
displayed a decrease in antinociception, an effect local-
ized to the raphe magnus and the thalamus based on
patch clamp recordings (Marubio and Changeux,
2000). Other work suggests that the NCS contributes
to performance of both passive avoidance and water
maze testing via circuitry that involves both the amyg-
dala and the nucleus basalis, while implantation of
nicotinic receptor-modulating compounds in the AMY
decreased FSH release (Piva et al., 1980; Riekkinen et
al., 1993).
Administration of CNQX also decreased 4 subunit
mRNA expression in the MHN. The MHN links the
limbic forebrain with diencephalic structures and me-
diates diverse neurophysiological functions, including
sensory gating, reward pathways, and stereotyped mo-
tor behaviors (Ellison, 1994). One study demonstrated
that heteromeric nAChRs accounted for 75% of nico-
tine-induced currents in the medial MHN, a population
that may include 4-containing receptors (Quick et al.,
1999). Interestingly, amphetamine and cocaine in-
duced degeneration of neurons in the lateral MHN,
while a different study demonstrated that administra-
tion of high levels of nicotine tartrate led to neurotox-
icity in the medial MHN (Carlson et al., 2001; Ellison,
2002). In both of these studies, neuropathologic
changes were observed in the fasciculus retroflexus, an
output tract of the MHN. These studies implicate the
NCS in the MHN as a possible substrate for stimulant-
mediated pathophysiology. Our data suggest a direct
interface between the glutamatergic and nicotinic cho-
linergic systems in the MHN.
Increases in 2 subunit transcript expression in the
SEP following CNQX treatment may be explained by
previous work that has demonstrated expression of
NMDA, AMPA, and KA receptors on cholinergic neu-
rons in the SEP (Kumamoto and Murata, 1995). Atten-
uation of AMPA receptor activation with CNQX would
decrease NMDA receptor activation, decreasing cal-
cium influx, altering intracellular signaling pathways,
and generation of excitatory postsynaptic currents. In-
terestingly, administration of CNQX by microdialysis
into the medial septum decreased ACh release, sug-
gesting that increased 2 subunit expression is second-
ary to diminished release of ACh (Moor et al., 1996).
However, 7 days of intravenous administration of the
nAChR agonists nicotine and/or mecamylamine did not
alter 2 mRNA expression in the SEP, suggesting that
regulation of subunit expression involves more than an
alteration in the synaptic level of neurotransmitter or
agonist (Pauly et al., 1996).
While expression of subunits that comprise both het-
ero- and homomeric nAChRs has been demonstrated in
the Pir, we only detected changes in 2 transcript
expression in this region (Wada et al., 1989). To our
knowledge, the interface of the glutamatergic and nic-
otinic cholinergic systems in the Pir has not previously
been examined. In the Pir, ACh release enhanced long-
term potentiation, likely contributing to associative
memory function (Barkai and Hasselmo, 1997; Patil et
al., 1998; Linster and Hasselmo, 2001). More work is
needed to assess the relevance of increased 2 subunit
expression in the Pir following CNQX treatment.
A limitation of this study is that we only measured
nAChR subunit transcript expression. For example,
while we did not detect a change in 7 subunit mRNA
expression, there may have been a change in 7 sub-
unit translation or 7 receptor mobilization to the cell
Fig. 9. 3, 3, and 4 nicotinic receptor subunit transcript expres-
sion in the medial habenula (MHN) following 7 days of CNQX treat-
ment. Expression of these transcripts did not differ between CNQX-
and vehicle-treated groups. There were 10 rats in each treatment
group.
TABLE I. Summary of changes in nicotinic receptor subunit expression following treatment with CNQX
Region HPC Fr SEP Pir Cg Par THA MHN HT AMY Te OT
Heteromeric 
subunits
2 1 – – – – – – – – – – –
3 – – – – – – – – – – – –
4 nc nc nc nc nc nc nc 2 nc 2 – –
5 – nc nc – nc – – nc – – nc –
Heteromeric 
subunits
2 1 nc 1 1 nc nc nc nc nc nc – nc
3 – – – – – – – nc – – – –
4 – – – – – – – nc – – – –
Homomeric subunit 7 nc nc nc nc nc nc nc – nc nc – –
Abbrieviations: increased (1) or decreased (2) transcript expression, no change detected (nc), not measured (–), amygdala (AMY), cingulate cortex (Cg),
6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), hypothalamus (HT), hippocampus (HPC), medial habenula (MHN), olfactory tubercle (OT), parietal cortex (Par),
piriform cortex (Pir), frontal cortex (Fr), septum (SEP), temporal cortex (Te), thalamus (THA).
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surface following CNQX treatment. Furthermore, an
alteration in transcript expression does not necessarily
indicate an alteration in expression of functional recep-
tors. Despite these limitations, our findings may be
conservatively interpreted to indicate an important in-
teraction between these excitatory neurotransmitter
systems.
This study demonstrates alterations in nAChR sub-
unit transcript expression following treatment with
CNQX, an AMPA and KA receptor antagonist, suggest-
ing a regulatory interface between the nicotinic cholin-
ergic and glutamatergic neurotransmitter systems.
Changes in transcript expression were confined to a
subset of nAChR subunits associated with heteromeric
receptor channels, supporting the hypothesis that ex-
pression of phenotypically distinct nicotinic receptor
subtypes is differentially regulated by CNQX via mod-
ulation of non-NMDA ionotropic glutamate receptors.
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